Citations

Clear

196 citation(s) found for "Schultz, M".

Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma
Bell, Erica H. , Shaw, Edward G. , Buckner, Jan C. , Barger, Geoffrey, Bullard, Dennis E., Brown, Paul D. , Stelzer, K. , McElroy, Joseph P., Fleming, Jessica L. , Timmers, Cynthia , Salavaggione, Andrea L., Aldape, Kenneth , Brachman, David, Gertler, Stanley Z., Murtha, Albert , Schultz, Christopher J. , Hunter, G.K., Crocker, Ian , Won, Minhee , Chakravarti, Arnab , Chakravarti, Arnab , Chakravarti, Arnab , Zhang, Jianwen , Mehta, Minesh P. , Gilbert, Mark R. , Becker, Aline Paixão , Liu, Ziyan , Johnson, David, Laack, Nadia N.

Mayo Clinic

Journal of Clinical Oncology | July 24, 2020 | Volume: 38 | Issue: 29 | Pages: 3407-3417

10.1200/jco.19.02983 | PMID 32706640 Get It

PURPOSENRG Oncology/RTOG 9802 (ClinicalTrials.gov Identifier: NCT00003375 ) is a practice-changing study for patients with WHO low-grade glioma (LGG, grade II), as it was the first to demonstrate a survival benefit of adjuvant chemoradiotherapy over radiotherapy. This post hoc study sought to determine the prognostic and predictive impact of the WHO-defined molecular subgroups and corresponding molecular alterations within NRG Oncology/RTOG 9802.METHODSIDH1/2 mutations were determined by immunohistochemistry and/or deep sequencing. A custom Ion AmpliSeq panel was used for mutation analysis. 1p/19q codeletion and MGMT promoter methylation were determined by copy-number arrays and/or Illumina 450K array, respectively. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method. Hazard ratios (HRs) were calculated using the Cox proportional hazard model and tested using the log-rank test. Multivariable analyses (MVAs) were performed incorporating treatment and common prognostic factors as covariates.RESULTSOf the eligible patients successfully profiled for the WHO-defined molecular groups (n = 106/251), 26 (24%) were IDH-wild type, 43 (41%) were IDH-mutant/non-codeleted, and 37(35%) were IDH-mutant/codeleted. MVAs demonstrated that WHO subgroup was a significant predictor of PFS after adjustment for clinical variables and treatment. Notably, treatment with postradiation chemotherapy (PCV; procarbazine, lomustine (CCNU), and vincristine) was associated with longer PFS (HR, 0.32; P = .003; HR, 0.13; P < .001) and OS (HR, 0.38; P = .013; HR, 0.21; P = .029) in the IDH-mutant/non-codeleted and IDH-mutant/codeleted subgroups, respectively. In contrast, no significant difference in either PFS or OS was observed with the addition of PCV in the IDH-wild-type subgroup.CONCLUSIONThis study is the first to report the predictive value of the WHO-defined diagnostic classification in a set of uniformly treated patients with LGG in a clinical trial. Importantly, this post hoc analysis supports the notion that patients with IDH-mutant high-risk LGG regardless of codeletion status receive benefit from the addition of PCV.
Surgical Revascularization in Children with Sickle Cell Disease and Moyamoya Syndrome
Kruchten, Matthew C. , Han, Sabrina, Hayward, Kelsey, Schultz, C., Gassie, Kelly , Carroll, Eliza, Aldana, Philipp R. , Schultz, Corinna L. , Piatt, Joseph H. , Schultz, Corinna , Gassie, Kelly , Hanel, Ricardó A.

Mayo Clinic

No container title available | June 10, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.159183143.32965939 Get It

Background: Pediatric patients with sickle cell disease (SCD) and moyamoya syndrome (MMS) are at high risk for recurrent cerebrovascular accidents (CVA) despite best conservative management with chronic blood transfusions (CBT). The role of surgical revascularization in this patient population is not clearly defined. We aim to compare the risk of stroke occurrence in patients undergoing conservative treatment to those additionally undergoing surgical revascularization with conservative treatment. Methods: The authors performed a retrospective cohort study of pediatric SCD-MMS patients seen in Jacksonville and Delaware between 2006 and 2018. Patient characteristics and outcomes, including stroke occurrence, were compared between those who underwent conservative treatment and those who underwent surgical revascularization. Results: A total 17 patients diagnosed with SCD-MMS were on CBT, of which 12 (70.6%) were female. The average age at CBT initiation was 7.27 years. Prior to its initiation, 10 patients (83%) in the surgical and 6 (75%) in the conservative group experienced strokes. Twelve patients underwent surgical revascularization on 18 hemispheres (17 indirect, 1 direct) for severe vasculopathy or CVA - this included 2 patients who experienced a stroke while receiving CBT. The degree of vasculopathy was worse in the surgical group. The mean follow-up for conservative and surgical groups were 11.8 and 4.4 years, respectively. Three patients experienced strokes in the conservative group, while no strokes or major complications were observed in the surgical group. Conclusion: Surgical revascularization appears safe and may effectively reduce stroke rates in pediatric patients with SCD-MMS. Larger studies are needed to confirm these findings.
Expanding the clinical and phenotypic heterogeneity associated with biallelic variants in ACO2
Blackburn, Patrick R. , Lahner, Carrie A., Bhoj, Elizabeth , Fisher, Laura J., Renaud, Deborah L. , Kenney, Amy, Ibrahim, Niema, Hashem, Mais, Seidahmed, Mohammed Zain , Hasadsri, Linda , Alkuraya, Fowzan S. , Lanpher, Brendan C. , Ongie, Laura , Alkuraya, Fowzan S , Bhoj, Elizabeth J , Schultz, Matthew , Li, Dong , Hashem, Mais, Vergano, Samantha A. Schrier

Mayo Clinic

Annals of Clinical and Translational Neurology | June 10, 2020 | Volume: 7 | Issue: 6 | Pages: 1013-1028

10.1002/acn3.51074 | PMID 32519519 Get It

AbstractObjectiveWe describe the clinical characteristics and genetic etiology of several new cases within the ACO2‐related disease spectrum. Mitochondrial aconitase (ACO2) is a nuclear‐encoded tricarboxylic acid cycle enzyme. Homozygous pathogenic missense variants in the ACO2 gene were initially associated with infantile degeneration of the cerebrum, cerebellum, and retina, resulting in profound intellectual and developmental disability and early death. Subsequent studies have identified a range of homozygous and compound heterozygous pathogenic missense, nonsense, frameshift, and splice‐site ACO2 variants in patients with a spectrum of clinical manifestations and disease severities.MethodsWe describe a cohort of five novel patients with biallelic pathogenic variants in ACO2. We review the clinical histories of these patients as well as the molecular and functional characterization of the associated ACO2 variants and compare with those described previously in the literature.ResultsTwo siblings with relatively mild symptoms presented with episodic ataxia, mild developmental delays, severe dysarthria, and behavioral abnormalities including hyperactivity and depressive symptoms with generalized anxiety. One patient presented with the classic form with cerebellar hypoplasia, ataxia, seizures, optic atrophy, and retinitis pigmentosa. Another unrelated patient presented with ataxia but developed severe progressive spastic quadriplegia. Another patient demonstrated a spinal muscular atrophy‐like presentation with severe neonatal hypotonia, diminished reflexes, and poor respiratory drive, leading to ventilator dependence until death at the age of 9 months.InterpretationIn this study, we highlight the importance of recognizing milder forms of the disorder, which may escape detection due to atypical disease presentation.
Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab
Badar, Talha , Szabó, Anikó , Advani, Anjali S. , Wadleigh, Martha , Arslan, Shukaib , Siebenaller, Caitlin, Schultz, Elizabeth, Shallis, Rory M. , Yurkiewicz, Ilana R. , Patel, Anand , Curran, Emily , Yang, Jay , Mattison, Ryan J. , Dinner, Shira, Liedtke, Michaela , Litzow, Mark R. , Patel, Anand , Badar, Talha , Advani, Anjali S , Khan, Muhammad Ali , Aldoss, Ibrahim , Schultz, Elizabeth, Hefazi, Mehrdad , Podoltsev, Nikolai , Balasubramanian, Suresh , Burkart, Madelyn , Atallah, Ehab

Mayo Clinic

Blood Advances | May 26, 2020 | Volume: 4 | Issue: 10 | Pages: 2308-2316

10.1182/bloodadvances.2019001381 | PMID 32453836 Get It

Abstract The availability and use of blinatumomab symbolizes a paradigm shift in the management of B-cell acute lymphoblastic leukemia (ALL). We conducted a retrospective multicenter cohort analysis of 239 ALL patients (227 relapsed refractory [RR], n = 227; minimal residual disease [MRD], n = 12) who received blinatumomab outside of clinical trials to evaluate safety and efficacy in the “real-world” setting. The median age of patients at blinatumomab initiation was 48 years (range, 18-85). Sixty-one (26%) patients had ≥3 prior therapies and 46 (19%) had allogeneic hematopoietic cell transplantation before blinatumomab. The response rate (complete remission/complete remission with incomplete count recovery) in patients with RR disease was 65% (47% MRD−). Among 12 patients who received blinatumomab for MRD, 9 (75%) patients achieved MRD negativity. In patients with RR disease, median relapse-free survival and overall survival (OS) after blinatumomab was 32 months and 12.7 months, respectively. Among patients who received blinatumomab for MRD, median relapse-free survival was not reached (54% MRD− at 2 years) and OS was 34.7 months. Grade ≥3 cytokine release syndrome, neurotoxicity, and hepatotoxicity were observed in 3%, 7%, and 10% of patients, respectively. Among patients who achieved complete remission/complete remission with incomplete count recovery, consolidation therapy with allogeneic hematopoietic cell transplantation retained favorable prognostic significance for OS (hazard ratio, 0.54; 95% confidence interval, 0.30-0.97; P = .04). In this largest “real-world” experience published to date, blinatumomab demonstrated responses comparable to those reported in clinical trials. The optimal sequencing of newer therapies in ALL requires further study.
Rhabdomyosarcoma of the female genital tract: Long-term outcome and association with DICER1 variation.
Kebudi, Rejin , Bay, Sema Büyükkapu , Görgün, Ömer, Dural, Özlem , Önder, Semen , Bılgıç, Bilge , Yılmaz, İsmail , İribaş, Ayça, Arndt, Carola A.S., Harris, Anne K. , Field, Amanda , Schultz, Kris Ann P. , Hill, Ashley, Darendeliler, Emin

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: 10538-10538

10.1200/jco.2020.38.15_suppl.10538 Get It

10538 Background: Rhabdomyosarcoma (RMS) of the female genital tract is rare, accounting for 3.5% of cases of rhabdomyosarcomas. Germline DICER1 mutations are associated with predisposition to pleuropulmonary blastoma and other tumors including sarcomas. Recently DICER1-associated RMS of the uterus/ovary has ben reported.. The aim of this study is to evaluate demographic characteristics, molecular pathogenesis, treatment and long term outcome of female genital tract rhabdomyosarcoma. Methods: Files of children with RMS of the female genital tract diagnosed at the Istanbul University, Oncology Institute during 1990-2019 were reviewed. Molecular genetic sequencing was performed by polymerase chain reaction amplification of genomic DNA extracted from the formalin-fixed, paraffin embedded tumors, followed by Sanger sequencing. Genetic testing for DICER1 variants of the proband and family members was performed if DICER1 mutation was detected in the tumor of the proband. Results: Of 210 RMS cases, 11 arose from the female genital tract. The median age at diagnosis was 52 months (10 months-15 years). Primary sites were vaginal (n = 5), uterus (n = 4), and ovary(n = 2). Presenting symptoms included vaginal mass (n = 6), vaginal bleeding (n = 5), and abdominal pain (n = 3). Four had group 1, five group 3, two group 2 disease and all received chemotherapy (vincristine, actinomycinD + cyclophosphamide).Three received radiotherapy; three underwent hysterectomy. DICER1 mutation was detected in tumor tissue in three patients:[ c.5113G > A (p.E1705K); c.5428G > T (p.D1810Y); c.1870C > T (p.Arg624Ter)] Genetic testing revealed germline DICER1 pathogenic variation in two patients and their family members, one of whom had cystic nephroma in infancy and history of Wilms tumor in an uncle. They were referred for surveillance for the DICER1 related diseases. A patient with metachronous bilateral ovarian RMS died. Two are married, one has children. The 5 year survival for RMS of the female genital tract was 85.7 % at a median follow-up of 34 (4-298) months. Conclusions: Rhabdomyosarcoma of the female genital tract is associated with a favorable prognosis, however some individuals undergo aggressive local therapies. Individuals with RMS of the female genital tract should be tested for DICER1 pathogenic variation. The detection of a DICER1 mutation in an individual or family members is important to facilitate surveillance for related tumors, so that they may be detected at the earliest possible stage, potentially increasing survival and decreasing risks of late effects.
Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT
Holtan, Shernan G. , Wang, Tao , Hemmer, Michael, Arora, Mukta , Couriel, Daniel R. , Pidala, Joseph, Abdel‐Azim, Hisham , Ahmed, Ibrahim , Al‐Homsi, A. Samer, Aljurf, Mahmoud , Antin, Joseph H. , Askar, Medhat , Auletta, Jeffery J. , Daly, Andrew , DeFilipp, Zachariah , Gajewski, James , Hematti, Peiman , Hildebrandt, Gerhard , Inamoto, Yoshihiro , Martino, Rodrigo , Majhail, Navneet S. , Marks, David I. , Pawarode, Attaphol , Prestidge, Tim , Rangarajan, Hemalatha G. , Ringdén, Olle , Saad, Ayman , Schoemans, Hélène , Seo, Sachiko , Solh, Melhem , Spitzer, Thomas R. , Storek, Jan , Verdonck, Leo F. , Wirk, Baldeep , Cahn, Jean‐Yves , Weisdorf, Daniel J. , Saad, Ayman , Ringden, Olov , Weisdorf, Dan , Majhail, Navneet S , Martino, Rodrigo , Holtan, Shernan , Auletta, Jeffery J , Hematti, Peiman , Mehta, Rohtesh S. , Spellman, Stephen R. , Alousi, Amin Majid , Agrawal, Vaibhav , Bhatt, Vijaya Raj , Chee, Lynette Chui Yen , Chhabra, Saurabh , Gale, Robert Peter , Gergis, Usama , Hogan, William J. , Nishihori, Taiga , Olsson, Richard F. , Díaz, Miguel Ángel , Savani, Bipin N. , Schultz, Kirk R. , Teshima, Takanori , Yared, Jean A.

Mayo Clinic

Journal of Clinical Oncology | May 4, 2020 | Volume: 38 | Issue: 18 | Pages: 2062-2076

10.1200/jco.19.00396 | PMID 32364845 Get It

PURPOSE There is no consensus on the best choice of an alternative donor (umbilical cord blood [UCB], haploidentical, one-antigen mismatched [7/8]–bone marrow [BM], or 7/8-peripheral blood [PB]) for hematopoietic cell transplantation (HCT) for patients lacking an HLA-matched related or unrelated donor. METHODS We report composite end points of graft-versus-host disease (GVHD)–free relapse-free survival (GRFS) and chronic GVHD (cGVHD)–free relapse-free survival (CRFS) in 2,198 patients who underwent UCB (n = 838), haploidentical (n = 159), 7/8-BM (n = 241), or 7/8-PB (n = 960) HCT. All groups were divided by myeloablative conditioning (MAC) intensity or reduced intensity conditioning (RIC), except haploidentical group in which most received RIC. To account for multiple testing, P < .0071 in multivariable analysis and P < .00025 in direct pairwise comparisons were considered statistically significant. RESULTS In multivariable analysis, haploidentical group had the best GRFS, CRFS, and overall survival (OS). In the direct pairwise comparison of other groups, among those who received MAC, there was no difference in GRFS or CRFS among UCB, 7/8-BM, and 7/8-PB with serotherapy (alemtuzumab or antithymocyte globulin) groups. In contrast, the 7/8-PB without serotherapy group had significantly inferior GRFS, higher cGVHD, and a trend toward worse CRFS (hazard ratio [HR], 1.38; 95% CI, 1.13 to 1.69; P = .002) than the 7/8-BM group and higher cGVHD and trend toward inferior CRFS (HR, 1.36; 95% CI, 1.14 to 1.63; P = .0006) than the UCB group. Among patients with RIC, all groups had significantly inferior GRFS and CRFS compared with the haploidentical group. CONCLUSION Recognizing the limitations of a registry retrospective analysis and the possibility of center selection bias in choosing donors, our data support the use of UCB, 7/8-BM, or 7/8-PB (with serotherapy) grafts for patients undergoing MAC HCT and haploidentical grafts for patients undergoing RIC HCT. The haploidentical group had the best GRFS, CRFS, and OS of all groups.
Protein‐elongating mutations inMYH11are implicated in a dominantly inherited smooth muscle dysmotility syndrome with severe esophageal, gastric, and intestinal disease
Gilbert, Melissa A. , Schultz‐Rogers, Laura , Wilkins, Benjamin J. , Biswas, Sawona , Conlin, Laura K. , Fiorino, Kristin, Dhamija, Radhika , Pack, Michael , Klee, Eric W. , Piccoli, David A., Spinner, Nancy B. , Spinner, Nancy B , Dhamija, Radhika , Rajagopalan, Ramakrishnan , Grochowski, Christopher M.

Mayo Clinic

Human Mutation | January 16, 2020 | Volume: 41 | Issue: 5 | Pages: 973-982

10.1002/humu.23986 | PMID 31944481 Get It

Randomized Controlled Trial of Mobile Closed-Loop Control
Kovatchev, Boris , Anderson, Stacey M. , Raghinaru, Dan, Kudva, Yogish C. , Laffel, Lori M. , Pinsker, Jordan E. , Buckingham, Bruce A. , Doyle, Francis J. , Brown, Sue A. , Church, Mei Mei , Dadlani, Vikash, Dassau, Eyal , Ekhlaspour, Laya , Forlenza, Gregory P. , Isganaitis, Elvira , Lam, David W. , Lum, John W. , Group, iDCL Study, Emory, Emma, Voelmle, Mary, Conshafter, Katie, Morris, Kim, Mitchell, Harry, Calvo, Kayla, Wakeman, Christian, Breton, Marc D. , Ambler-Osborn, Louise, Flint, Emily, Schultz, Alan , Kim, Kenny, Church, Mei Mei, André, Camille , Lam, David W., O’Malley, Grenye , Levister, Camilla, Ogyaadu, Selassie, Simha, Vinaya , McCrady-Spitzer, Shelly , Reid, Corey, Jost, Emily , Berget, Cari , Towers, Lindsey, Buckingham, Bruce, Ekhlaspour, Laya, Hsu, Liana, Loebner, Sarah E., Doyle, Francis J., Campos, Tiffany, Passman, Samantha, Murphy, Carlos, Patibandla, Nandan, Kollman, Craig, Pinsker, Jordan E , Doyle, Francis J , Dassau, Eyal , Ekhlaspour, Laya , Forlenza, Gregory P , Lum, John , Kovatchev, Boris , Buckingham, Bruce , Levy, Carol J. , Wadwa, R Paul , Beck, Roy W. , Group, iDCL Study, Oliveri, Mary Clancy , Church, Mei Mei, Lam, David W., Messer, Laurel H , Buckingham, Bruce, Ekhlaspour, Laya, Doyle, Francis J., Kollman, Craig

Mayo Clinic

Diabetes Care | January 15, 2020 | Volume: 43 | Issue: 3 | Pages: 607-615

10.2337/dc19-1310 | PMID 31937608 Get It

OBJECTIVE Assess the efficacy of inControl AP, a mobile closed-loop control (CLC) system. RESEARCH DESIGN AND METHODS This protocol, NCT02985866, is a 3-month parallel-group, multicenter, randomized unblinded trial designed to compare mobile CLC with sensor-augmented pump (SAP) therapy. Eligibility criteria were type 1 diabetes for at least 1 year, use of insulin pumps for at least 6 months, age ≥14 years, and baseline HbA1c &lt;10.5% (91 mmol/mol). The study was designed to assess two coprimary outcomes: superiority of CLC over SAP in continuous glucose monitor (CGM)–measured time below 3.9 mmol/L and noninferiority in CGM-measured time above 10 mmol/L. RESULTS Between November 2017 and May 2018, 127 participants were randomly assigned 1:1 to CLC (n = 65) versus SAP (n = 62); 125 participants completed the study. CGM time below 3.9 mmol/L was 5.0% at baseline and 2.4% during follow-up in the CLC group vs. 4.7% and 4.0%, respectively, in the SAP group (mean difference −1.7% [95% CI −2.4, −1.0]; P &lt; 0.0001 for superiority). CGM time above 10 mmol/L was 40% at baseline and 34% during follow-up in the CLC group vs. 43% and 39%, respectively, in the SAP group (mean difference −3.0% [95% CI −6.1, 0.1]; P &lt; 0.0001 for noninferiority). One severe hypoglycemic event occurred in the CLC group, which was unrelated to the study device. CONCLUSIONS In meeting its coprimary end points, superiority of CLC over SAP in CGM-measured time below 3.9 mmol/L and noninferiority in CGM-measured time above 10 mmol/L, the study has demonstrated that mobile CLC is feasible and could offer certain usability advantages over embedded systems, provided the connectivity between system components is stable.
SPECC1L regulates palate development downstream of IRF6
Hall, Everett G. , Wenger, Luke W., Wilson, Nathan R. , Undurty-Akella, Sraavya S, Standley, Jennifer , Augustine-Akpan, Eno-Abasi, Kousa, Youssef A. , Acevedo, Diana S., Goering, Jeremy P., Pitstick, Lenore, Natsume, Nagato , Paroya, Shahnawaz, Busch, Tamara , Mori, Akihiro , Schultz‐Rogers, Laura , Klee, Eric W. , Babovic‐Vuksanovic, Dusica , Kroc, Sarah A., Eshete, Mekonen , Bjork, Bryan C. , Suzuki, Satoshi , Murray, Jeffrey C. , Schutte, Brian C. , Butali, Azeez , Saadi, Irfan , Schultz-Rogers, Laura E, Babovic-Vuksanovic, Dusica, Wilson, Nathan R, Augustine‐Akpan, Eno‐Abasi, Ito, Masaaki, Mori, Akihiro, Imura, Hideto , Adeyemo, Wasiu Lanre

Mayo Clinic

Human Molecular Genetics | January 6, 2020 | Volume: 29 | Issue: 5 | Pages: 845-858

10.1093/hmg/ddaa002 | PMID 31943082 Get It

Abstract SPECC1L mutations have been identified in patients with rare atypical orofacial clefts and with syndromic cleft lip and/or palate (CL/P). These mutations cluster in the second coiled-coil and calponin homology domains of SPECC1L and severely affect the ability of SPECC1L to associate with microtubules. We previously showed that gene-trap knockout of Specc1l in mouse results in early embryonic lethality. We now present a truncation mutant mouse allele, Specc1lΔC510, that results in perinatal lethality. Specc1lΔC510/ΔC510 homozygotes showed abnormal palate rugae but did not show cleft palate. However, when crossed with a gene-trap allele, Specc1lcGT/ΔC510 compound heterozygotes showed a palate elevation delay with incompletely penetrant cleft palate. Specc1lcGT/ΔC510 embryos exhibit transient oral epithelial adhesions at E13.5, which may delay shelf elevation. Consistent with oral adhesions, we show periderm layer abnormalities, including ectopic apical expression of adherens junction markers, similar to Irf6 hypomorphic mutants and Arhgap29 heterozygotes. Indeed, SPECC1L expression is drastically reduced in Irf6 mutant palatal shelves. Finally, we wanted to determine if SPECC1L deficiency also contributed to non-syndromic (ns) CL/P. We sequenced 62 Caucasian, 89 Filipino, 90 Ethiopian, 90 Nigerian and 95 Japanese patients with nsCL/P and identified three rare coding variants (p.Ala86Thr, p.Met91Iso and p.Arg546Gln) in six individuals. These variants reside outside of SPECC1L coiled-coil domains and result in milder functional defects than variants associated with syndromic clefting. Together, our data indicate that palate elevation is sensitive to deficiency of SPECC1L dosage and function and that SPECC1L cytoskeletal protein functions downstream of IRF6 in palatogenesis.
Reporting Practices and Resource Utilization in the Era of Intraductal Carcinoma of the Prostate
Gandhi, Jatin , Smith, Steven C. , Paner, Gladell P. , McKenney, Jesse K. , Sekhri, Radhika , Osunkoya, Adeboye O. , Baras, Alexander S. , Cheville, John C. , Jiménez, Rafael E. , Trpkov, Kiril , Colecchia, Maurizio , Ro, Jae Y. , Montironi, Rodolfo , Hes, Ondřej , Hirsch, Michelle S. , Netto, George J. , Fine, Samson W. , Sirohi, Deepika , Kaushal, Seema , Robinson, Brian D. , Kweldam, Charlotte F. , Humphrey, Peter A. , Hansel, Donna E. , Schultz, Luciana , Przybycin, Christopher G. , Mehra, Rohit , Kunju, Lakshmi P., Aron, Manju , Kuroda, Naoto , Tavora, Fabio, Grignon, David J. , Epstein, Jonathan I. , Reuter, Victor E. , Amin, Mahul B. , Távora, Fábio , Robinson, Brian D. , Trpkov, Kiril , Marzo, Angelo M. De , Menon, Santosh , Williamson, Sean R. , Sangoi, Ankur R. , Magi‐Galluzzi, Cristina , Shah, Rajal B. , Kryvenko, Oleksandr N. , Kench, James G. , Kwast, Theodorus van der

Mayo Clinic

American Journal of Surgical Pathology | December 24, 2019 | Volume: 44 | Issue: 5 | Pages: 673-680

10.1097/pas.0000000000001417 | PMID 31876580 Get It

Intraductal carcinoma of the prostate (IDC-P) has been recently recognized by the World Health Organization classification of prostatic tumors as a distinct entity, most often occurring concurrently with invasive prostatic adenocarcinoma (PCa). Whether documented admixed with PCa or in its rare pure form, numerous studies associate this entity with clinical aggressiveness. Despite increasing clinical experience and requirement of IDC-P documentation in protocols for synoptic reporting, the specifics of its potential contribution to assessment of grade group (GG) and cancer quantitation of PCa in both needle biopsies (NBx) and radical prostatectomy (RP) specimens remain unclear. Moreover, there are no standard guidelines for incorporating basal cell marker immunohistochemistry (IHC) in the diagnosis of IDC-P, either alone or as part of a cocktail with AMACR/racemase. An online survey containing 26 questions regarding diagnosis, reporting practices, and IHC resource utilization, focusing on IDC-P, was undertaken by 42 genitourinary subspecialists from 9 countries. The degree of agreement or disagreement regarding approaches to individual questions was classified as significant majority (>75%), majority (51% to 75%), minority (26% to 50%) and significant minority (≤25%). IDC-P with or without invasive cancer is considered a contraindication for active surveillance by the significant majority (95%) of respondents, although a majority (66%) also agreed that the clinical significance/behavior of IDC-P on NBx or RP with PCa required further study. The majority do not upgrade PCa based on comedonecrosis seen only in the intraductal component in NBx (62%) or RP (69%) specimens. Similarly, recognizable IDC-P with GG1 PCa was not a factor in upgrading in NBx (78%) or RP (71%) specimens. The majority (60%) of respondents include readily recognizable IDC-P in assessment of linear extent of PCa at NBx. A significant majority (78%) would use IHC to confirm or exclude intraductal carcinoma if other biopsies showed no PCa, while 60% would use it to confirm IDC-P with invasive PCa in NBx if it would change the overall GG assignment. Nearly half (48%, a minority) would use IHC to confirm IDC-P for accurate Gleason pattern 4 quantitation. A majority (57%) report the percentage of IDC-P when present, in RP specimens. When obvious Gleason pattern 4 or 5 PCa is present in RP or NBx, IHC is rarely to almost never used to confirm the presence of IDC-P by the significant majority (88% and 90%, respectively). Most genitourinary pathologists consider IDC-P to be an adverse prognostic feature independent of the PCa grade, although recommendations for standardization are needed to guide reporting of IDC-P vis a vis tumor quantitation and final GG assessment. The use of IHC varies widely and is performed for a multitude of indications, although it is used most frequently in scenarios where confirmation of IDC-P would impact the GG assigned. Further study and best practices recommendations are needed to provide guidance with regards to the most appropriate indications for IHC use in scenarios regarding IDC-P.